10 New Drugs for Primary Care: Q2 2018

One in Ten Individuals Initiate GLP-1 Therapy Within 5 Years of Bariatric Surgery, Study Finds

Slideshow

What new drugs should you know about from the second quarter of 2018? Scroll through our quick slideshow to find out.

Related Content

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

In a trial of over 112 000 US adults, researchers found that 14% started a GLP-1 receptor agonist after bariatric surgery.

Shingles Vaccine Linked to Reduced Cardiovascular Risk in Global Meta-Analysis: ESC Preview

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

ESC 2025: The first global investigation of evidence for the potential positive connection is encouraging, but more research is needed to understand causality.

Linda Stein Gold, MD;Sydney Jennings

August 25th 2025

Evommune Launches Phase 2b Trial of Oral MRGPRX2 Antagonist, EVO756, In Adults With Atopic Dermatitis

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

New Vaccine Guidance from the American College of Cardiology Focuses on Adults with Heart Disease

MRGPRX2 antagonism is the only known mechanism of action designed to modulate mast cells and sensory neurons, both key drivers of lesions and itch in AD.

One in Ten Individuals Initiate GLP-1 Therapy Within 5 Years of Bariatric Surgery, Study Finds

New ACC guidance emphasizes the critical role of vaccinations in reducing infection risks and improving outcomes for adults with cardiovascular disease.

Related Content

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

In a trial of over 112 000 US adults, researchers found that 14% started a GLP-1 receptor agonist after bariatric surgery.

Shingles Vaccine Linked to Reduced Cardiovascular Risk in Global Meta-Analysis: ESC Preview

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

ESC 2025: The first global investigation of evidence for the potential positive connection is encouraging, but more research is needed to understand causality.

Linda Stein Gold, MD;Sydney Jennings

August 25th 2025

Evommune Launches Phase 2b Trial of Oral MRGPRX2 Antagonist, EVO756, In Adults With Atopic Dermatitis

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

New Vaccine Guidance from the American College of Cardiology Focuses on Adults with Heart Disease

MRGPRX2 antagonism is the only known mechanism of action designed to modulate mast cells and sensory neurons, both key drivers of lesions and itch in AD.